Current Clinical Recommendations for Use of Platelet-Rich Plasma

被引：226
作者：
Le A.D.K. [1 ,2 ]
Enweze L. [1 ]
DeBaun M.R. [1 ]
Dragoo J.L. [1 ]
机构：
[1] Department of Orthopedic Surgery, Stanford University, 450 Broadway St, Redwood City, CA
[2] Lifemark Health Group, Toronto, ON
来源：
Current Reviews in Musculoskeletal Medicine | 2018年 / 11卷 / 4期
关键词：
Orthobiologics; Osteoarthritis; Platelet-rich plasma; PRP; Regenerative medicine; Tendinopathy;
D O I：
10.1007/s12178-018-9527-7
中图分类号：
学科分类号：
摘要：
Purpose of Review: This review evaluates current clinical literature on the use of platelet-rich plasma (PRP), including leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP), in order to develop evidence-based recommendations for various musculoskeletal indications. Recent Findings: Abundant high-quality evidence supports the use of LR-PRP injection for lateral epicondylitis and LP-PRP for osteoarthritis of the knee. Moderate high-quality evidence supports the use of LR-PRP injection for patellar tendinopathy and of PRP injection for plantar fasciitis and donor site pain in patellar tendon graft BTB ACL reconstruction. There is insufficient evidence to routinely recommend PRP for rotator cuff tendinopathy, osteoarthritis of the hip, or high ankle sprains. Current evidence demonstrates a lack of efficacy of PRP for Achilles tendinopathy, muscle injuries, acute fracture or nonunion, surgical augmentation in rotator cuff repair, Achilles tendon repair, and ACL reconstruction. Summary: PRP is a promising treatment for some musculoskeletal diseases; however, evidence of its efficacy has been highly variable depending on the specific indication. Additional high-quality clinical trials with longer follow-up will be critical in shaping our perspective of this treatment option. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
页码：624 / 634
页数：10
相关论文
共 104 条
  • [1] Boswell S.G., Cole B.J., Sundman E.A., Karas V., Fortier L.A., Platelet-rich plasma: a milieu of bioactive factors, Arthroscopy, 28, pp. 429-439, (2012)
  • [2] Foster T.E., Puskas B.L., Mandelbaum B.R., Gerhardt M.B., Rodeo S.A., Platelet-rich plasma: from basic science to clinical applications, Am J Sports Med, 37, pp. 2259-2272, (2009)
  • [3] Le A., Dragoo J.L., Orthobiologics: Clinical application of platelet-rich plasma and stem cell therapy, Delee Drezs Orthop Sports Med
  • [4] Le A.D., Enweze L., Debaun M.R., Dragoo J.L., Platelet-rich plasma, Clin Sports Med, 20, pp. XX-XX, (2018)
  • [5] Marx R.E., Platelet-rich plasma (PRP): what is PRP and what is not PRP?, Implant Dent, 10, pp. 225-228, (2001)
  • [6] Degen R.M., Bernard J.A., Oliver K.S., Dines J.S., Commercial separation systems designed for preparation of platelet-rich plasma yield differences in cellular composition, HSS J, 13, pp. 75-80, (2017)
  • [7] Magalon J., Bausset O., Serratrice N., Giraudo L., Aboudou H., Veran J., Magalon G., Dignat-Georges F., Sabatier F., Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model, Arthroscopy, 30, pp. 629-638, (2014)
  • [8] Castillo T.N., Pouliot M.A., Kim H.J., Dragoo J.L., Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems, Am J Sports Med, 39, pp. 266-271, (2011)
  • [9] Dragoo J.L., Braun H.J., Durham J.L., Ridley B.A., Odegaard J.I., Luong R., Arnoczky S.P., Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons, Am J Sports Med, 40, pp. 1274-1281, (2012)
  • [10] Mazzocca A.D., McCarthy M.B.R., Chowaniec D.M., Cote M.P., Romeo A.A., Bradley J.P., Et al., Platelet-rich plasma differs according to preparation method and human variability, J Bone Joint Surg Am, 94, pp. 308-316, (2012)
12345678910